A growing number of in vitro studies suggest that recombinant human stem cell factor (SCF) is capable of augmenting the proliferative capacity of human hematopoietic progenitor cells (HPC) and stem cells (HSC). We further evaluated this biologic effect by analyzing the response of bone marrow (BM) HPCs and HSCs to the administration of SCF in eight patients with locally advanced or metastatic breast cancer who were enrolled in an ongoing phase I study. SCF was administered for 14 days by daily subcutaneous injection at dosages of 10.25, or 50 pg/kg/ d. BM CD34' HLA-DR+ and CD34+ HLA-DR-CD15-cells, previously shown by our laboratory to be enriched for various classes of differentiated and primitive HPCs, respectively, were quantitated in BM samples on day 0 (pretreatment) and day 15 (posttreatment). These CD34+ HLA-DR+ and CD34+ HLA-DR-CD15-cells were then isolated by cell-sorting and assayed for several classes of HPCs, including the high-proliferative potential colonyforming cell (HPP-CFC), the burst-forming unit-megakaryocyte (BFU-MK), and the long-term BM culture-initiating cell (LTBMC-IC). SCF administration resulted in a 3.3-fold (range, 1.4-to 18.8-fold; P = .018) increase in the absolute numbers of CD34+ cells, a 3.7-fold (range, 1.2-to 8.2-fold; P = .028) increase in the absolute numbers of CD34+ HLA-DR+ cells, and a 2.4-fold (range, 1.1-to 29.3-fold; P = .010) increase in the absolute numbers of CD34+ HLA-DR-CD15-cells. Following the infusion of SCF, a statistically significant increase in the absolute UMAN BONE MARROW (BM) is composed of a
The publication costs of this article were defiayed in part by page charge payment. This article must therefore he hereby marked numbers of HPP-CFC (P = .018), BFU-MK (P = .046), CFU-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM; P = .043), BFU-erythrocyte (BFU-E; P = .043), CFU-granulocyte, macrophage (CFU-GM; P = .045), and CFU-megakaryocyte (CFU-MK; P = ,028) per milliliter of marrow was observed. Stromal cell-free LTBMCs supplemented with SCF and interleukin-3 (IL-3). initiated with CD34+ HLA-DR-CD15-cells obtained on day 0, produced viable cells for 9.6 weeks, compared with 11.5 weeks for LTBMCs initiated with CD34+ HLA-DR-CD15-cells obtained on day 15. Cumulative cellular production by LTBMCs initiated with day 15 CD34+ HLA-DR-CD15-cells was statistically greater than that by day 0 LTBMCs (P = .031). These same cultures produced CFU-GM for 6.3 weeks (day 0) versus 9 weeks (day 15). Cumulative production of CFU-GM during the period of LTBMC was statistically greater when day 1 5 CD34+ HLA-DR-CDI 5-cells served as the initiating cell population compared with the same subpopulation obtained on day 0 (2.1 -to 18-fold increase; P = .OlO). We conclude that the in vivo administration of SCF to humans results in a statistically significant expansion in numbers and proliferative capacity of both differentiated and primitive HPCs. These studies suggest that in vivo SCF administration may be useful for improving the quality of BM grafts to be used for both autologous and allogeneic BM transplantation. Recently, a number of cytokines have been shown to be capable of expanding in vitro the number of marrow HPCs and possibly HSCS.~.'~ One cytokine that potentially might be particularly useful for these purposes is recombinant methionyl human stem cell factor (SCF).9-'2 SCF is a ligand for the c-kit proto-oncogene and has been shown to play an important role in events that occur during human hematopoiesi~.'~-'~ Although SCF itself does not promote colony formation, it synergistically enhances the ability of other growth factors such as erythropoietin (Epo), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-3 (IL-3) to promote in vitro the formation not only of differentiated progenitor cells, but also of various primitive These primitive HPCs include the colonyforming unit-blast (CFU-Bl), the high-proliferative potential colony-forming cell (HPP-CFC), the burst-forming unit-megakaryocyte (BFU-MK), and the long-term BM culture-initiating cell (LTBMC-IC).6.9"23'9,20 The CFU-B1, HPP-CFC, and LTBMC-IC each has extensive self-renewal potential and multilineage differentiation ~a p a c i t y .~' .~~ Cell populations enriched for these primitive HPCs have recently been shown to have multilineage marrow-populating ability, suggesting that such cells resemble HSCs.9-12320,24 Recently, Andrews et al provided some evidence that the in vivo administration of SCF to primates might result in an increase in the absolute number of colony-forming unit-granulocyte, macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-E) present in m a r r~w . *~,~~ This apparent expansion of detectable HPCs in primates was attributed to either enhanced self-renewal of committed HPC or expansion of HSC numbers.
In this report, we present data on the in vivo effects of SCF administration on human BM HPCs and HSCs. We obtained BM samples from eight women with locally advanced or metastatic breast cancer who were enrolled in an ongoing phase I study of recombinant methionyl human SCF (r-metHuSCF). The clinical results of this trial will be reported elsewhere. Our findings indicate that in vivo administration of SCF leads not only to an expansion in the BM of committed progenitor cells, but also to an increase in the number of primitive HPCs that resemble HSC. These data suggest that treatment in vivo with SCF might result in the expansion ofthe components of a marrow graft responsible for engraftment following marrow transplantation.
MATERIALS AND METHODS
Eight women with locally advanced (stage IIIB) or metastatic (stage IV) breast cancer, enrolled in an ongoing phase I trial of r-metHuSCF (Amgen, Thousand Oaks, CA) were studied. All patients had entry hematologic parameters including an absolute neutrophil count 2 2,000 cells/pL, platelet count 2 lOO,OOO/ pL, and hemoglobin concentration 2 9 g/dL. Trephine biopsies were obtained immediately before (day 0) and after completion of the r-metHuSCF treatment (day 15). BM biopsy specimens were processed as previously reported by Orazi et al.'' No patient had evidence of tumor-cell involvement of BM. Patients received rmetHuSCF by daily subcutaneous injection at dosages of 10, 25, and 50 pg/kg/d for 14 consecutive days before the delivery of cytotoxic chemotherapy. Standard BM aspirations for progenitor assays were performed before (pretreatment, day 0) and following completion of the 14 days of therapy (posttreatment, day 15). Patients who had received adjuvant chemotherapy for breast cancer 6 months before this study were eligible for entry. The study was approved by the Institutional Review Board of The Indiana University School of Medicine. The clinical results of this study will be presented elsewhere.
Small BM samples (1 to 2 mL) were aspirated from numerous sites of the posterior iliac crest of patients after informed consent was obtained according to the guidelines established by the Human Investigation Committee of the Indiana University School of Medicine. These aspirates were pooled and low-density mononuclear cells (LDBM) were isolated by density centrifugation. Heparinized marrow cells were layered over FicollPaque (Pharmacia Fine Chemicals, Piscataway, NJ) and centrifuged at 500g for 25 minutes. Since no significant changes in BM cellularity were noted following SCF administration, all subsequent data were reported as changes in cell phenotype or progenitor cell numbers per volume of marrow in order to correct for any qualitative changes of hematopoietic cells that might be caused by SCF. 
CeNseparation techniques.
consisted of the corresponding isotype-matched, nonspecific myeloma proteins used in parallel with the staining monoclonal antibodies. Cells were stained at a concentration of 8 X 107/mL and washed with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS). Immediately after staining, cells were sorted on a Coulter Epics 753 dual-laser flow cytometer (Coulter Electronics, Hialeah, FL) equipped with a CICERO high-speed computer (Cytomation, Fort Collins, CO). FITC and PE were excited using the 488-nm wavelength from a dedicated 5-W argon laser. Cells were first gated on forward-angle light scatter. In such a staining protocol, it was still possible to obtain CD34+ HLA-DR+ cells, even though both HLA-DR and CD15 were FITC-conjugated. Cells stained with both markers display two distinct green fluorescence peaks. The "dim" peak corresponding to HLA-DR is between 1 and I .5 log less fluorescent than the "bright" peak corresponding to CDl5. Simultaneous staining with PE-conjugated CD34, FITC-HLA-DR, and FITC-CDI5 allows for the detection of CD34' HLA-DR-CD15-, CD34' HLA-DR+, and CD34' CD15+ cells. Sorting windows were established to collect CD34' HLA-DR-CD15-and CD34+ HLA-DR+ cells only. The CD34' DR+ cell population has previously been shown to be enriched for differentiated marrow progenitor cells (CFU-GM, BFU-E, CFU-megakaryocyte [CFU-MK], and CFU-granulocyte, erythrocyte, monocyte, megakaryocyte [CFU-GEMM])6, while the CD34' HLA-DRCDl5-cell population has been reported to be enriched for several classes of primitive HPCs (CFU-B1, HPP-CFC, BFU-MK, r-metHuSCF (specific activity, 5 X lo5 U/mg), IL-3 (specific activity, IO5 U/mg), and GM-CSF (specific activity, lo7 U/mg) were obtained from Amgen. Human urine Epo (specific activity, 34.8 U/mg) was purchased from Toyobo, Japan.
Long-term suspension cultures. Stromal cell-free LTBMC were initiated and maintained as previously described?-" Sorted cells (1 X 104/mL CD34+ HLA-DR-CDl5-cells) were seeded on day 0 in flat-bottomed 24-well plates in 1 mL Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum (FCS), SCF (100 ng/mL), and IL-3 (1 ng/mL), and incubated at 37°C in 100% humidified air with 5% CO2. Every 48 hours thereafter, cultures received SCF (100 ng/mL) and IL-3 (1 ng/mL). At weekly intervals, the cultures were demidepopulated by the removal of half of the culture volume, which was then replaced by fresh medium and cytokines. Cells in the harvested medium were counted and assayed for CFU-GM and BFU-E.
HPC assays. Freshly sorted cells (1 X 1 03/mL CD34+ HLA-DR+ or 1 X 103/mL CD34' HLA-DR-CD15-cells) and cellular aliquots obtained from LTBMC ( I X 1 04/mL) were suspended in 35-mm plastic tissue culture dishes (Costar Data Packing, Cambridge, MA) containing 1 mL of 30% FCS, 5 X lo-' mol/mL 2-mercaptoethanol, 1 U human urinary Epo/mL, 100 ng/mL SCF, 1 ng/mL IL-3, 200 pg/mL GM-CSF, and 1.1% methylcellulose in IMDM. These cultures were incubated at 37°C in 100% humidified air with 5% CO,. After 14 days, CFU-GM, BFU-E, and CFU-GEMM colonies were enumerated in situ using an inverted microscope and standard criteria for their identification. HPP-CFC in the cultures initiated with CD34+ HLA-DR-CDl5-cells were scored after 28 days of incubation according to previously established criteria."
BFU-MK initiated with 5 X IO3 CD34+ DR-CD15-cells per milliliter and CFU-MK initiated with 5 X lo3 CD34+ DR+ cells per milliliter were assayed in a serum-depleted medium previously detailed by Briddell et Cells were suspended in a I-mL serumsubstituted fibrin clot with 100 ng/mL SCF and 1 ng/mL I L 3 in 35-mm culture dishes and incubated at 37°C in a 100% humidified LTBMC-IC).6.7s9-1 1. 20 Hematopoietic growthfactors.
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From 786 TONG ET AL atmosphere containing 5% CO, in air. After 12 days (CFU-MK) or 2 1 days (BFU-MK), the cultures were fixed in situ and stained using rabbit antihuman platelet glycoprotein antisera, and FTTC-conjugated goat F(ab)2-specific anti-rabbit IgG (Tago, Burlingame, CA). CFU-MK and BFU-MK colonies were enumerated on a fluorescence microscope according to previously established criteria.'* Statistical analysis. The results, expressed as the mean & SEM, were obtained from duplicate experiments. Statistical significance was determined using the Wilcoxon signed-ranks t-test.
RESULTS
Pretreatment BM cellularity as assessed by trephine biopsies was normal in all patients (45.5% k 3.7%) on day 0 and was increased to 55.2% k 11% following SCF treatment. This increment in cellularity was not statistically significant (P > .05). The effect of SCF administration on marrow HPC and HSC numbers was initially assessed by monitoring the changes in the marrow phenotype following SCF administration. The number of CD34' cells per milliliter of marrow was used as a measure of both marrow HPC and HSC numbers, while the number of CD34+ HLA-DR' cells per milliliter of marrow was used as a means of quantitating HPC and the number of CD34+ HLA-DR-CD 15-cells per milliliter of marrow served as a means of quantitating changes in HSC numbers ( Table 1) . As shown in Table 1 , in vivo SCF administration resulted in remarkable increases in the numbers of CD34+, CD34' HLA-DR+, and CD34+ HLA-DR-CD 15-cells per milliliter of marrow. These data were quantitated in this fashion to correct for any changes in marrow cellularity produced by SCF administration. A 1.3-to 8.5-fold increase (P = .O 18) in the number of CD34+ cells was observed, while a 1.2-to 8.2-fold increase (P = .028) in the number of CD34+ HLA-DR+ cells and a 1,l to 29.1 -fold increase (P = .010) in the number of CD34+ HLA-DR-CD 15-cells were seen. By contrast, numbers of peripheral blood CD34+ cells did not increase following SCF administration (data not shown).
The effect of SCF administration on the absolute number of assayable HPCs per milliliter of BM following SCF administration was also examined. Figure 1 shows the absolute numbers of committed progenitor cells assayed from CD34' HLA-DR+ cells both before and after SCF administration. SCF administration resulted in a statistically significant increase in the absolute numbers of CFU-GM (1 3.7 k 3.9X 103/mLv3.1k 1.1 X I03/mL;P=.045),BFU-E(14.1 f 6.9 X 103/mL v 2.3 f 1.0 X 103/mL; P = .043), CFU-MK (0.5 ? 0. I X 103/mL v 0.2 & 0.1 X 103/mL; P = .028), and = .043) (Fig I) . The number of CFU-GEMM cloned from 1 X lo3 CD34+ HLA-DR+ cells obtained from day 15 marrow cells was statistically (P = .020) greater than that cloned from an equivalent number of day 0 CD34' HLA-DR+ cells (data not shown). Such a statistically significant increment in cloning efficiency was not observed for the other classes of more differentiated progenitor cells (CFU-GM, BFU-E, CFU-MK) (data not shown). Furthermore, SCF therapy had a profound effect on the absolute numbers of primitive HPCs assayed from CD34+ HLA-DR-CD15-marrow cells. In each patient studied, the numbers of HPP-CFC and BFU-MK increased following SCF treatment. There was a mean 97. (Fig 2) . Neither BFU-MK nor HPP-CFC were assayable from CD34' HLA-DR+ cells either before or after SCF therapy (data not shown).
The effect of SCF administration on the ability of CD34+ HLA-DR-CD 15-cells to initiate and sustain long-term hematopoiesis in vitro was also assessed (Tables 2 and 3 (Table 2 ). Cumulative cellular production by LTBMC initiated with day 15 CD34' HLA-DR-CD15-cells was statistically significantly greater than that produced by day 0 LTBMC (29 k 10 X lo6 cells/mL culture v 16 f 10 X IO6 cells/mL culture; P = .031) ( Table 2) . Furthermore, CFU-GM were assayed from LTBMC initiated with CD34' HLA-DR-CD15-cells obtained on day 0 for an average of 6.3 weeks (range, 4 to 8), while LTBMC initiated with CD34+ HLA-DR-CD15-cells obtained on day 15 produced assayable CFU-GM for an average of 8.7 weeks (range, 8 to IO) ( Table 3) . Cumulative production of CFU-GM during the total period of LTBMC was also statistically greater (P = .010) when day 15 CD34' HLA-DR-CD 15-cells served as the initiating cell population than when the same subpopulation obtained on day 0 was used to initiate the LTBMC (2.1-to IS-fold
increase; 22 k 10 X 103/mL culture v 8.6 f 7 X 103/mL culture) ( Table 3) . Erythropoiesis in LTBMC initiated with day 15 CD34+ HLA-DR-CD15-cells was sustained for 2 to 4 weeks, while cultures initiated with day 0 CD34+ HLA-DR-CDI 5-cells generated BFU-E for only 0 to 2 weeks (Table 4) . Cumulative production of BFU-E during the period of LTBMC was greater when day 15 CD34' HLA-DR-CD 15-cells served as the IC population than when the same population obtained on day 0 was used to initiate the LTBMC (325 * 200/mL culture v 152 f 110/mL culture; P = .037) ( Table  4) . However, this increment in cumulative BFU-E production during LTBMC was far smaller than that observed with CFU-GM production during the same period of LTBMC.
Cohorts of patients were treated with various doses of SCF (patients no. 1 to 3, 10 pg/kg; patients no. 4 to 6, 50 pg/kg; patients no. 7 and 8,25 pg/kg) for 14 days. There was no significant difference in the effects of SCF on HSC or HPC observed at the various doses administered (Tables 1  through 4 ).
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DISCUSSION
Soluble SCF has a wide range of effects in vitro on hematopoietic cells.'a'' SCF acts synergistically with other hematopoietic growth factors to promote the proliferation and development of multipotential and unipotential HPCS.'~'' These synergistic interactions result not only in an increase in the numbers of hematopoietic colonies formed, but also in the size of such colonies.'@'' In addition, SCF is known to have a profound effect in vitro on the proliferative capacity of primitive human HPCs (CFU-BI, HPP-CFC, BFU-MK, LTBMC-IC).la'* Using monoclonal antibodies to c-kit, this receptor has been shown to be present on both primitive and differentiated human H P C S . '~,~~,~~ Such findings indicate that SCF and c-kit not only are important regulators of more differentiated classes of HPCs, but that they likely also play a pivotal role in cytokine regulation of To clarify further the effects of SCF on hematopoiesis, several groups have administered SCF to normal rodents and primate^.^^^^^^^'"^ Ulich et a1 reported that a single injection of recombinant rat SCF resulted in a rapid increase in rat marrow erythroid precursors, as well as causing a dosedependent neutrophilia and lymphocyto~is.~' Andrews et a1 investigated the effects of prolonged administration of human SCF to primates.25p26 SCF administered to baboons for 7, 14, and 2 1 days resulted in increased numbers of peripheral blood cells belonging to myeloid and lymphoid lineages, as well as increased cellularity of the BM.25 When SCF was administered to primates at a dose of 200 pg/kg/d for 7 to 28 days, it resulted in an increased frequency of CD34+ cells and a 10-to 100-fold increase in numbers of committed progenitor cells assayable from the peripheral blood.26 However, the effects of SCF on marrow progenitors, were less pronounced. Following 21 and 28 days of SCF, the numbers of CFU-GM and BFU-E assayed from marrow were not statistically increased.25 However, these data were thought to indicate expansion of the absolute numbers of marrow CFU-GM and BFU-E due to pronounced increases in marrow cellularity that occurred following administration of this ~y t o k i n e .~~ pg/mL GM-CSF, and 1 U/mL Epo. Individual cultures for CFU-GM were enumerated on day 14.
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In the present phase I study of SCF administered to breast cancer patients, we hoped to determine the effects of this cytokine on both BM HPC and HSC. When data from each of the doses of SCF administered were analyzed, statistically significant increases in the number of CD34+ cells present within the marrow were observed. To assure that our data would not be affected by cell losses encountered following density centrifugation of BM samples, our results are reported on a per volume basis. Examination of trephine biopsies after SCF administration did not show a significant increase in BM cellularity. Therefore, the observations reported here cannot be accounted for by increases in absolute marrow cell numbers, but rather are due to increases in the numbers of specific marrow cell populations. When CD34' HLA-DR' marrow cells were assayed for CFU-GM, BFU-E, CFU-GEMM, and CFU-MK following SCF administration, a statistically significant expansion in the numbers of each of these HPCs was observed. The early phases of marrow engraftment following transplantation are thought not to be the consequence of primitive HPC, but due to the infusion of more committed
The increase in CFU-GM, BFU-E, CFU-GEMM, and CFU-MK numbers following in vivo SCF administration reported here suggests that the period of pancytopenia following the delivery of myeloablative therapy might be shortened by the infusion of a graft harvested following SCF administration.
The expansion in the number of progenitor cells reported in the peripheral blood of primates following SCF administration suggested to Andrews et al that an additional in vivo action of SCF was on a precursor cell of differentiated progenitor cells.25 A number of laboratories have shown that the HPCs likely arise from a group of primitive hematopoietic cells that resemble HSCs. We chose, therefore, to examine directly the response of human HSCs to SCF by quantitating the effects of the administration of this cytokine on various classes of primitive SCF administration resulted in a statistically significant increase in the numbers of HPP-CFC and BFU-MK. This increase in numbers of assayable HPP-CFC and BFU-MK is likely due to the ability of SCF to promote either self-renewal or proliferation of these two classes of primitive HPCs. Recently, our group has demonstrated the ability of SCF in vitro to enhance both HPP-CFC and BFU-MK cloning effi~i e n c y .~' " .~~ The LTBMCs initiated with CD34' HLA-DR-CD15-cells obtained following SCF therapy generated significantly greater numbers of committed progenitor cells for longer periods of time than that observed with cells obtained before SCF therapy. The prolonged duration and enhanced cell production of LTBMCs initiated with marrow obtained following SCF administration could be due to either the presence of greater numbers of LTBMC-IC within the CD34' HLA-DR-CDI 5-marrow population used to initiate such cultures or to an increased proliferative capacity of individual LTBMC-ICs. Additional studies in which actual numbers of LTBMC-IC will be quantitated following SCF administration are currently being planned in our laboratory to resolve this question.
Expansion of the numbers of marrow CD34+ HLA-DR-CD15-cells, HPP-CFC, BFU-MK, and the greater cellular and progenitor cell output of LTBMCs initiated with cells obtained after SCF administration, suggest that a major in vivo effect of SCF is on the most primitive classes of HPCs. Studies in the murine system have related the numbers of HPP-CFC and LTBMC-IC to in vivo marrow repopulating ability of a cellular graft delivered following lethal irradiat i~n .~' ,~' Furthermore, Srour et al, using an in utero fetal sheep transplantation model, demonstrated that CD34+ HLA-DR-cells are capable of establishing sustained multilineage hematopoiesis in chimeric animals.24 Therefore, the absolute increases in CD34' HLA-DR-CD15-cells, BFU-MK, HPP-CFC, and likely LTBMC-IC following in vivo SCF treatment indicate that such a treatment might lead to an expansion of marrow HSC numbers. In this report, administration of increasing doses of SCF to patients did not result in a further change in the number of cells expressing a particular phenotype or progenitor cell number. However, such a dose-response relationship was observed when SCF was administrated at much higher doses (200 pg/kg/d) to nonhuman primatesz6 The lack of a dose-response relationship reported here could be due to a variety of reasons, including (1) species differences, (2) small patient sample size, or (3) use of relatively low doses of SCF. Further examination of larger numbers of patients being treated at higher doses of SCF will be required to determine if such a dose-response relationship exists in humans.
Recently, Zsebo et a1 reported the radioprotection of mice
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From by recombinant rat SCF.32 They attributed this effect to SCF stimulating the proliferation of radioprotective cells and promoting the cycling of these cells into late S-phase, where they are no longer vulnerable to the effects of radiation3* In addition, Briddell et al have shown that SCF actually synergizes with G-CSF in increasing the numbers of murine marrow repopulating cells.33 These reports, in addition to our own data, raise the possibility that grafts harvested following in vivo SCF administration alone or in combination with other cytokines might contain greater numbers of cells that are responsible for sustained long-term hematopoietic engraftment. Such grafts might be an excellent target for therapeutic gene transfer therapy, since they would potentially contain greater numbers of HSCs, which also might be actively cycling and thereby be optimal for gene transfer.3941
In the present study, SCF administration did not result in an increase in the numbers of peripheral blood CD34+ cells. However, Andrews et a1 previously reported major increases in CD34' cell numbers in the peripheral blood of nonhuman primates following administration of much higher doses of SCF.26 Our inability to detect such an increase is likely due merely to a lack of administration of higher doses of this growth factor. Further studies of HPC and HSC expansion following in vivo SCF administration therefore appear warranted to provide additional information concerning the potential use of SCF to affect the cellular content of marrow grafts to be used for autologous and/ or allogeneic marrow transplantation.
